Lineage Cell News Today

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They currently have a $7.00 price objective on the stock. Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $6.00 price target on shares of […]

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX – Get Free Report) saw a significant increase in short interest in the month of June. As of June 30th, there was short interest totalling 6,440,000 shares, an increase of 19.0% from the June 15th total of 5,410,000 shares. Based on an average daily volume of 715,600 shares, the short-interest […]

And Donald Trump files a countersuit against E. Jean Carroll.

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX – Get Rating) – Equities research analysts at HC Wainwright raised their FY2027 earnings per share (EPS) estimates for Lineage Cell Therapeutics in a research note issued to investors on Friday, May 12th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of $0.00 per share […]

An allogeneic retinal pigment epithelial cell therapy may help slow disease progression in geographic atrophy secondary to age-related macular degeneration, according to a press release from Lineage Cell Therapeutics.

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX – Get Rating) traded up 2.2% on Monday . The company traded as high as $1.42 and last traded at $1.40. 487,492 shares changed hands during mid-day trading, an increase of 41% from the average session volume of 346,562 shares. The stock had previously closed at $1.37. Wall Street Analyst […]

This week in cell therapy weekly: license agreements, manufacturing collaborations and more! Get all the latest news on RegMedNet.com.

/PRNewswire/ -- DelveInsights Age-related Macular Degeneration Market Insights report includes a comprehensive understanding of current treatment practices,...

/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the expansion of its board of directors with the appointment of Peter García, a...

Markets In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Aravive (ARAV – Research Report), with a price target of $26.00. The company’s shares closed last Tuesday at $6.14. According to TipRanks.com, Pantginis is a top 100 analyst with an average return of 41.0% and a 62.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Catabasis Pharmaceuticals, and Lineage Cell Therapeutics. The wo...